Growth hormone treatment in the United States: Demographic and diagnostic features of 2331 children

August, Gilbert P.; Lippe, Barbara M.; Blethen, Sandra L.; Rosenfeld, Ron G.; Seelig, Steven; Johanson, Ann J.; Compton, Peter; Frane, James W.; McClellan, Barbara H.; Sherman, Barry M.

doi:10.1016/s0022-3476(05)80647-x

Cited by 95 publications

(45 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with the data in the literature, boys outnumbered girls in all aetiology groups (4,15,17,18). In patients with idGHD, the ratio of males to females in our study is, however, lower than that reported in other studies (1.5 in Belgium versus 2.5 (USA) (15), 3.1 (Sweden) (17), 1.9 (UK) (17), 2.0 (France) (17), 2.6 (Germany) (17) and 2.0 (KIGS) (18)).…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001

Thomas¹,

Massa

Craen³

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Since the availability of recombinant human growth hormone (rhGH) all children with growth hormone deficiency (GHD) living in Belgium are offered rhGH treatment after approval by a peer -review board. In this study, we evaluated the prevalence and demographic features of childhood GHD in Belgium during the period 1986 -2001 and we compared them with the data from other countries. Methods: Diagnostic, demographic and baseline auxological data of 714 children diagnosed as having GHD between 1986 and 2001 were retrieved from the database of the Belgian Study Group for Paediatric Endocrinology. Results: The prevalence of GHD in Belgium was estimated to be 1/5600. The origin of GHD was idiopathic (idGHD) in 41% of the patients, congenital (congGHD) in 20% and acquired (acqGHD) in 35%. During the first 4 years (1986 -1989) more patients were classified as idGHD; thereafter the distribution between the three aetiology groups did not change. In all groups, boys outnumbered girls but this preponderance was especially pronounced in congGHD patients (male:female ¼ 4:1) with a central malformation that associates an anterior pituitary hypoplasia, a missing, fine or normal pituitary stalk and an ectopic posterior pituitary. Thirteen percent of the patients with idGHD, 50% with congGHD and 52% with acqGHD had multiple pituitary deficiencies. Patients with congGHD were the youngest (mean^S.D. age: 6.5^4.7 years) and were the shortest (2 3.0^1.3 standard deviation score (SDS)) at the start of rhGH treatment. There was no time trend over the studied period for age and height at onset of GH therapy. Conclusion: In Belgium, the prevalence of childhood GHD can be estimated as 1/5600 which is comparable to other recent surveys. The yearly number of new patients for the different aetiologies and the auxological parameters have remained relatively constant over the last 16 years.

show abstract

Section: Discussionsupporting

confidence: 87%

“…sex steroid priming) and/or between the considered time periods in the evaluation of short children for GHD. For the congGHD and acqGHD, the age at onset of rhGH therapy is comparable to other series (4,15,18). The age at onset of rhGH therapy did not change significantly in Belgium between 1986 and 2001 for the three groups.…”

Section: Discussionsupporting

confidence: 76%

Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001

Thomas¹,

Massa

Craen³

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Our finding is consistent with previous studies that have shown boys are more likely than girls to receive off-label medications, such as growth hormone for short stature. [17][18][19] We found that index off-label antihypertensives overall were more expensive from the payer perspective, compared with their on-label counterparts in 2002. However, older drugs with expired patent protection and generic equivalents, such as diuretics and β-blockers, were found to be less expensive prescribed off-label compared to their on-label counterparts in the same classes.…”

Section: Discussionmentioning

confidence: 94%

Off-Label Utilization of Antihypertensive Medications in Children

Yoon

Dombkowski

Rocchini

et al. 2007

Ambulatory Pediatrics

View full text Add to dashboard Cite

Objective-To examine off-label utilization and costs of antihypertensive drugs in children using a national sample of prescription claims.Design-Cross-sectional study. Setting-2002 Medstat MarketScanDatabase, a national sample of outpatient prescription claims of children ≤18 years old enrolled in private, employer-sponsored health plans.Main Outcome Measures-Off-label use of antihypertensive drugs by patient age and costs of antihypertensives calculated as mean cost per child per 30-day fill.Results-One-half of the index antihypertensive prescription claims were off-label, based on minimum age criteria. Boys were more likely (56%) than girls (46%) to be prescribed off-label antihypertensives (p<0.001). Children aged ≥12 years were more likely to be prescribed off-label antihypertensives (53%) compared with children aged ≤5 (46%) and 6-11 years (42%, p<0.001). Off-label use varied significantly by class of antihypertensive drugs (p<0.001). Overall, off-label antihypertensives were significantly more expensive than on-label antihypertensives.Conclusions-Despite availability of often less expensive on-label alternatives for the same class of antihypertensive drugs, off-label antihypertensive drugs were prescribed frequently in children. These findings underscore the potential clinical and economic implications of common off-label prescribing, for children, their parents, physicians and payers.

show abstract

“…The exact prevalence of this disorder is unknown in Algeria. In Europe and the United States, it is variously estimated and varies between 1/4000 and 1/10 000 (August et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

Final Height and Pubertal Development in 150 Children with Growth Hormone Deficiency in Algeria

Fedala¹,

Chentli²,

Meskine³

et al. 2015

ijccr

View full text Add to dashboard Cite

Summary Growth Hormone Deficiency (GHD) may happen when the body is unable to produce enough growth hormone (GH) or use it effectively. GH plays a fundamental role in helping young bodies grow and develop puberty. When levels of GH are too low, there may be an impact on growth and many functions of the body.We report in this study, the results on the final height and pubertal development of 150 Algerian patients followed in our department of endocrinology.

show abstract

Growth hormone treatment in the United States: Demographic and diagnostic features of 2331 children

Cited by 95 publications

References 7 publications

Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001

Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001

Off-Label Utilization of Antihypertensive Medications in Children

Final Height and Pubertal Development in 150 Children with Growth Hormone Deficiency in Algeria

Contact Info

Product

Resources

About